thesi updat wasnt market
expect ep print essenti line top line shortfal
disappoint appear come odd sourc
three headwind manag call seem reason
unfortun pop enthusiasm
space improv look forward much chang
forecast thesi see headwind manag
believ remedi effort alreadi underway aid
second half us real question come easi
comp core volum given storm saw prior year
whether pl deal step littl visibl
either margin low end manag forecast
revenu remain mid-point ep arent particularli
worri setup growth acceler beyond
remain place thesi quit simpl growth improv
payer slowli shift busi highli scale low cost provid
lh pick-up also aid ep growth
chang massiv slight upshift allow nearli doubl
digit tsr push multipl pariti market impli
return current level low teen risk adjust quit
appeal view buyer weak today
read lh make lh print tomorrow interest
today move also help de-risk furthermor much
lh thesi resid improv cro perform boost
iqv number today look share ralli line beat
compani expect pl relationship announc
help acceler growth
partnership progress smoothli confid
oper well locat addit build
unfavor trend three market prescript drug monitor
vitamin hep-c drove soft volum quarter
trend hamper quarter broadli
increment commentari around better trend market
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
chang
 revenu growth vs prior
 reflect perform
 expect growth acceler
 take action area pbm vitamin test
 expect pl agreement close
 last year hurrican impact make easier comp major impact
carryov
 prescript drug monitor make progress payor chang view
 vitamin optimist increas educ around appropri vitamin test
 hep-c challeng persist certainli mitig busi remain drug
requir test
trend seen quarter
 prescript drug monitor growth strong less expect polici chang oppos payer
limit test
 got one payor chang posit
 hep-c faster expect declin genotyp resist test due rapid accept new hep-
 vitamin test slow due increas reimburs denial
 outsid trend organ growth steadi last number quarter
 volum increas acquisit contribut bp
 softer expect due three trend
 price headwind consist
 headwind bp pama less bp factor
 headwind mention substant impact rev/req
 denial impact rev/req
patient price concess uncollect balanc flat yoy
 pre-nat test continu grow nice
 market gener stabl true routin portion women health busi
 continu slow declin pap busi
 gener volum women health busi continu stabl
revenu contribut flattish roughli contribut volum busi bought
similar core busi
alreadi detail account respect contract sale rep/geographi engag
contract includ mm
 mm includ invest acceler growth around advanc dx pbm
 sg larg portion cost sale invest volum come volum come
cost sale
 also includ expens relat clinic phlebotomist laboratori test ahead volum
unit lab spend north bn
contract tradit ff contract
 differ rate base perform
access unit greater
 access big state texa florida california greater
jan in-network vast major unh plan
activ detail need done defend share
 somewhat exclus provid well servic optum sell payor
 becom one biggest custom
 respect optum davita acquisit activ work better serv physician exist
account also grow list physician optum care
 continu build presenc
 store
 convers gotten broad deep meet today regard jv
 continu progress smoothli
 approach store result store great
 test work retail minut clinic
physician fee schedul modest tweak dont think notabl busi small piec
compani patholog busi materi
hope announc pl agreement
convers today year ago
quest diagnost stat million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut juli
valuat price target base dcf methodolog contempl wacc termin ebitda multipl
equat perpetu growth rate pt translat ebitda vs average
downsid risk challeng associ integr small outreach lab deal could depress return invest capit
prove distract recent vertic integr hc servic organ lead increas price pressur given heighten
focu unit cost potenti pama relat price cut bleed commerci price ultim lead neg
upsid risk pama repriev lead ep upward revis remov key growth overhang allow resumpt
pe expans open contract favor econom allow lh reap benefit expens small
player pressur small lab lead materi up-tick activ highli attract price allow notabl b/
laboratori corp america hold
articl articl
time dissemin juli et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
